# First Human Trial of Targeting MDM2/MDMX PET Imaging

> **NCT06443762** · EARLY_PHASE1 · COMPLETED · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 3 (actual)

## Conditions studied

- MDM2/MDMX Gene Mutation
- Nuclear Medicine
- Positron Emission Tomography Imaing

## Interventions

- **DRUG:** [68Ga] MDM2/MDMX Peptide

## Key facts

- **NCT ID:** NCT06443762
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-03
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-05-23
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06443762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06443762, "First Human Trial of Targeting MDM2/MDMX PET Imaging". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06443762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*